NO325920B1 - 1'-[4-[1-(4-Fluorfenyl)-1H-indol-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H)-4'-piperidin]hydrohalogenider - Google Patents

1'-[4-[1-(4-Fluorfenyl)-1H-indol-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H)-4'-piperidin]hydrohalogenider Download PDF

Info

Publication number
NO325920B1
NO325920B1 NO20002188A NO20002188A NO325920B1 NO 325920 B1 NO325920 B1 NO 325920B1 NO 20002188 A NO20002188 A NO 20002188A NO 20002188 A NO20002188 A NO 20002188A NO 325920 B1 NO325920 B1 NO 325920B1
Authority
NO
Norway
Prior art keywords
spiro
piperidine
butyl
indol
fluorophenyl
Prior art date
Application number
NO20002188A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002188L (no
NO20002188D0 (no
Inventor
Ole Nielsen
Niels Mork
Heidi Lopez De Diego
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20002188D0 publication Critical patent/NO20002188D0/no
Publication of NO20002188L publication Critical patent/NO20002188L/no
Publication of NO325920B1 publication Critical patent/NO325920B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20002188A 1997-11-07 2000-04-27 1'-[4-[1-(4-Fluorfenyl)-1H-indol-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H)-4'-piperidin]hydrohalogenider NO325920B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK126797 1997-11-07
PCT/DK1998/000480 WO1999024436A1 (en) 1997-11-07 1998-11-06 1'-[4-[1- (4-fluorophenyl)- 1h-indole-3-yl] -1-butyl]-spiro [isobenzofuran- 1(3h),4'- piperidine] hydrohalogenides

Publications (3)

Publication Number Publication Date
NO20002188D0 NO20002188D0 (no) 2000-04-27
NO20002188L NO20002188L (no) 2000-06-14
NO325920B1 true NO325920B1 (no) 2008-08-18

Family

ID=8102935

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002188A NO325920B1 (no) 1997-11-07 2000-04-27 1'-[4-[1-(4-Fluorfenyl)-1H-indol-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H)-4'-piperidin]hydrohalogenider

Country Status (38)

Country Link
US (2) US6844352B2 (cs)
EP (1) EP1044202B1 (cs)
JP (1) JP3605358B2 (cs)
KR (1) KR100399274B1 (cs)
CN (1) CN1105115C (cs)
AR (1) AR023010A1 (cs)
AT (1) ATE288918T1 (cs)
AU (1) AU749094B2 (cs)
BG (1) BG64906B1 (cs)
BR (1) BR9813949A (cs)
CA (1) CA2308745C (cs)
CZ (1) CZ288666B6 (cs)
DE (1) DE69828999T2 (cs)
DZ (1) DZ2642A1 (cs)
EA (1) EA002092B1 (cs)
EG (1) EG23791A (cs)
ES (1) ES2234162T3 (cs)
HR (1) HRP20000261B1 (cs)
HU (1) HUP0100991A3 (cs)
ID (1) ID25776A (cs)
IL (1) IL135723A (cs)
IS (1) IS2342B (cs)
JO (1) JO2052B1 (cs)
MA (1) MA25585A1 (cs)
NO (1) NO325920B1 (cs)
NZ (1) NZ504065A (cs)
PE (1) PE130299A1 (cs)
PL (1) PL190538B1 (cs)
PT (1) PT1044202E (cs)
RS (1) RS49777B (cs)
SK (1) SK285245B6 (cs)
TN (1) TNSN98201A1 (cs)
TR (1) TR200001267T2 (cs)
TW (1) TW483894B (cs)
UA (1) UA64769C2 (cs)
UY (1) UY25236A1 (cs)
WO (1) WO1999024436A1 (cs)
ZA (1) ZA9810116B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
WO2004026855A1 (en) * 2002-09-20 2004-04-01 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
US20050032827A1 (en) * 2003-06-12 2005-02-10 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
US20090306341A1 (en) * 2005-07-29 2009-12-10 Joachim Emmert LC/MS Blends Containing Ionizing Additives
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
TNSN98201A1 (fr) 2005-03-15
EP1044202A1 (en) 2000-10-18
IL135723A0 (en) 2001-05-20
JP3605358B2 (ja) 2004-12-22
AU749094B2 (en) 2002-06-20
IS2342B (is) 2008-02-15
CA2308745A1 (en) 1999-05-20
NZ504065A (en) 2002-05-31
HRP20000261A2 (en) 2001-04-30
WO1999024436A1 (en) 1999-05-20
US20030055074A1 (en) 2003-03-20
HRP20000261B1 (en) 2009-04-30
PT1044202E (pt) 2005-04-29
EP1044202B1 (en) 2005-02-09
PL340220A1 (en) 2001-01-15
TR200001267T2 (tr) 2000-09-21
DE69828999D1 (de) 2005-03-17
RS49777B (sr) 2008-06-05
NO20002188L (no) 2000-06-14
BG104485A (en) 2001-01-31
CN1105115C (zh) 2003-04-09
US6844352B2 (en) 2005-01-18
YU23500A (sh) 2003-12-31
KR20010031791A (ko) 2001-04-16
US20050171135A1 (en) 2005-08-04
CZ288666B6 (cs) 2001-08-15
SK285245B6 (sk) 2006-09-07
SK6462000A3 (en) 2000-10-09
EA002092B1 (ru) 2001-12-24
IL135723A (en) 2005-11-20
MA25585A1 (fr) 2002-12-31
AU1022699A (en) 1999-05-31
DE69828999T2 (de) 2005-07-21
JP2001522852A (ja) 2001-11-20
TW483894B (en) 2002-04-21
BR9813949A (pt) 2000-09-26
CA2308745C (en) 2004-01-20
ID25776A (id) 2000-11-02
UA64769C2 (uk) 2004-03-15
PL190538B1 (pl) 2005-12-30
IS5460A (is) 2000-04-18
NO20002188D0 (no) 2000-04-27
PE130299A1 (es) 1999-12-16
EA200000502A1 (ru) 2000-10-30
DZ2642A1 (fr) 2004-12-28
HUP0100991A3 (en) 2003-03-28
CZ20001663A3 (cs) 2000-10-11
CN1278823A (zh) 2001-01-03
HUP0100991A2 (hu) 2001-09-28
HK1034075A1 (en) 2001-10-12
ES2234162T3 (es) 2005-06-16
BG64906B1 (bg) 2006-08-31
ZA9810116B (en) 1999-05-07
KR100399274B1 (ko) 2003-09-26
AR023010A1 (es) 2002-09-04
ATE288918T1 (de) 2005-02-15
JO2052B1 (en) 1999-05-15
UY25236A1 (es) 2000-12-29
EG23791A (en) 2007-08-13

Similar Documents

Publication Publication Date Title
EP2062898B1 (de) Spirocyclische Cyclohexan-Derivate
RU2404972C2 (ru) Ингибиторы сигма-рецептора
US10273214B2 (en) Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
AU749094B2 (en) 1'-{4-{1- (4-fluorophenyl)- 1h-indole-3-yl} -1-butyl}-spiro {isobenzofuran- 1(3h),4'- piperidine} hydrohalogenides
CS264150B2 (en) Process for preparing new 1-/4-aminophenyl/-4-methyl-7,8-methylendioxy-3,4-dihydro-5h-2,3-benzodiazepine
ES2251316B1 (es) Inhibidores del receptor sigma.
Lattmann et al. Pre-Clinical Evaluation of CCK2 Antagonist PNB-001 (4-Chloro-5-Hydroxy-1-Phenylethyl-5-Phenyl-1, 5-Dihydro-Pyrrol-2-One) Towards The Design For A First-In-Man Clinical Trial
MXPA00004094A (en) 1'-[4-[1- (4-fluorophenyl)- 1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran- 1(3h),4'- piperidine]hydrohalogenides
WO2013083070A1 (zh) 1,4-二氢-萘啶衍生物及其药物组合物和用途
WO2023242809A1 (en) Crystalline forms of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1h,2h,3h,4h,5h-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one and salts thereof, method of preparation, and uses thereof
US7776903B2 (en) Pharmaceutical preparations containing substituted 2,5-diaminomethyl-1H-pyrroles
HK1034075B (en) 1'-[4-[1-(4-fluorophenyl)- 1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3h),4'-piperidine] hydrohalogenides
CN121717808A (zh) 咪唑并吡啶类衍生物及其制备方法、药物组合物和应用

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

MM1K Lapsed by not paying the annual fees